Atıf İçin Kopyala
Ozturk-Cerik H., Esen S., ALTINTAŞ ÖNER B., Celik M., Ozdemir T., TANYEL E.
KLIMIK JOURNAL, cilt.33, sa.3, ss.297-306, 2020 (ESCI)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
33
Sayı:
3
-
Basım Tarihi:
2020
-
Doi Numarası:
10.5152/kd.2020.60
-
Dergi Adı:
KLIMIK JOURNAL
-
Derginin Tarandığı İndeksler:
Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database
-
Sayfa Sayıları:
ss.297-306
-
Anahtar Kelimeler:
Hepatitis C, sofosbuvir, ledipasvir, ombitasvir, paritaprevir, dasabuvir, VIRUS GENOTYPE 1, 4 INFECTION, RIBAVIRIN, EFFICACY, LEDIPASVIR/SOFOSBUVIR, SOFOSBUVIR, SAFETY
-
Eskişehir Osmangazi Üniversitesi Adresli:
Evet
Özet
Objective: Hepatitis C virus (HCV) infection is a global problem with personal, social and economic impacts. Approximately 85% of patients infected with HCV cannot achieve virus clearance. Cirrhosis, hepatocellular carcinoma and death may develop in patients with chronic infection.Until recently, treatments for chronic hepatitis C were difficult to use with many side effects, low treatment responses, and relapses. Direct-acting antivirals (DAAs) prevent HCV replication, and thir effectiveness is over 90%. In this study, we aimed to evaluate the achievement of these treatments.